# US 2015/0104423 A1 · Use of blood group status iii

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104423 A1
- Document ID: US20150104423A1
- Status: Published application
- Kind: A1
- Application number: 14/577,072
- Filed: 2014-12-19
- Published: 2015-04-16
- Earliest claimed: 2010-07-26
- Assignees: Dupont Nutrition Biosciences Aps
- Applicants: Dupont Nutrition Biosciences Aps
- Inventors: Pirjo WACKLIN; Jaana MATTO; Harri MAKIVUOKKO; Jukka PARTANEN; Janne NIKKILA
- Web page: https://patentgrep.com/patent/US20150104423A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- C12Q 1/689: for bacteria
- C12Q 2600/156: Polymorphic or mutational markers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to a microbial composition which is tailored based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from the intestine of secretor individuals. The present invention further relates to a method of tailoring a microbial composition based on the spectrum of microbes found more frequently from the intestine of non-secretor individuals than from that of secretor blood group status. The present invention relates to use of the secretor status of an individual as a criterion for microbial supplementation tailored based on the differences in the spectra of microbes found between secretor and non-secretor individuals.

## Claims

### Claim at position 1

1-23. (canceled)

### Claim 24

A non-secretor/secretor genotype based microbial composition, wherein the composition is tailored based on the spectrum of bacteria found in the mucosal tissue of at least one individual with non-secretor or secretor blood group phenotype.

### Claim 25 (depends on 24)

The microbial composition according to claim 24, wherein the composition comprises at least one of the strains having any of the following genotypes:
band position 25.30%, 26.40%, 39.00%, 42.40%, 47.00%, 50.40%, 56.80% or 60.20% as defined by universal-DGGE analysis; or
band position 35.30%, 60.00%, 62.60% or 69.00% as defined by Eubacterium rectale-Clostridium coccoides-group (EREC)-DGGE analysis; or
band position 4.80%, 10.20%, 23.80%, 36.00%, 38.70% or 41.10% as defined by Bacteroides-DGGE analysis; or
band position 15.40%, 20.50%, 27.80%, 32.80%, 36.10%, 37.30%, 42.10%, 43.00%, 46.10%, 56.20%, 61.80% 73.30%, 79.10%, 85.00% or 91.80%, as defined by Clostridium leptum-DGGE analysis.

### Claim 26 (depends on 24)

The microbial composition of claim 24, wherein the composition is tailored based on the spectrum of bacteria found in the mucosal tissue of at least one individual with non-secretor blood group phenotype.

### Claim 27 (depends on 26)

The microbial composition according to claim 26, wherein the composition comprises at least one of the strains having any of the following genotypes:
band position 25.30%, 26.40%, 39.00%, 42.40%, 47.00%, 50.40%, 56.80% or 60.20% as defined by universal-DGGE analysis; or
band position 35.30%, 60.0% or 69.00% as defined by Eubacterium rectale-Clostridium coccoides-group (EREC)-DGGE analysis; or
band position 4.80%, 10.20%, 23.80%, 36.00%, 38.70% or 41.10% as defined by Bacteroides-DGGE analysis; or
band position 15.40%, 20.50%, 27.80%, 32.80%, 36.10%, 37.30%, 42.10%, 43.00%, 46.10%, 61.80%, 73.30%, 79.10%, 85.00% or 91.80% as defined by Clostridium leptum-DGGE analysis.

### Claim 28 (depends on 27)

The microbial composition according to claim 27, wherein the composition comprises two or more of the specified strains.

### Claim 29 (depends on 27)

The microbial composition according to claim 27, wherein the composition comprises at least one of the strains having any of the following bacterial genotypes
a) band position 25.30%, 26.40%, 50.40% or 56.80% as defined by universal-DGGE analysis; or
b) band position 60.0% as defined by Eubacterium rectale-Clostridium coccoides-group (EREC)-DGGE analysis; or
c) band position 4.80%, 10.20%, 23.80%, 38.70%, or 41.10% as defined by Bacteroides-DGGE analysis; or
d) band position 32.80%, 36.10%, 43.00%, 73.30%, 79.10%, 85.00%, or 91.80% as defined by Clostridium leptum-DGGE analysis.

### Claim 30 (depends on 29)

The microbial composition according to claim 29, wherein the composition comprises two or more of the specified strains.

### Claim 31 (depends on 24)

The microbial composition of claim 24, wherein the composition is tailored based on the spectrum of bacteria found in the mucosal tissue of at least one individual with secretor blood group phenotype.

### Claim 32 (depends on 31)

The microbial composition according to claim 31, wherein the composition comprises at least one of the strains having any of the following genotypes:
band position 62.60% as defined by Eubacterium rectale-Clostridium coccoides-group (EREC)-DGGE analysis; or
band position 56.20% as defined by Clostridium leptum-DGGE analysis.

### Claim 33 (depends on 31)

The microbial composition according to claim 31, wherein the composition comprises the strains having any of the following genotypes:
band position 62.60% as defined by Eubacterium rectale-Clostridium coccoides-group (EREC)-DGGE analysis; and
band position 56.20% as defined by Clostridium leptum-DGGE analysis.

### Claim 34 (depends on 24)

The microbial composition according to claim 24, wherein the composition is tailored based on the spectrum of non-bifidobacterial bacteria found in the mucosal tissue of at least one individual with non-secretor or secretor blood group phenotype.

### Claim 35 (depends on 24)

The microbial composition according to claim 24, wherein the said composition additionally includes at least one prebiotic agent.

### Claim 36 (depends on 24)

The microbial composition according to claim 24 for treating and/or preventing inflammatory bowel disease, diarrhoea, respiratory tract infections, irritable bowel syndrome, atopy/allergy, celiac disease and/or disturbed balance of mucosal microbiota followed by stem cell transplantation and/or subsequent graft-versus-host disease.

### Claim 37

A method of tailoring a microbial composition based on the spectrum of bacteria found in the mucosal tissue of at least one individual with non-secretor or secretor blood group phenotype.

### Claim 38 (depends on 37)

The method according to claim 37, wherein the method comprises steps:
determining secretor/non-secretor genotype of an individual,
determining the typical mucosal bacterial repertoire of the secretor/non-secretor type,
optionally manufacturing a microbial composition based on the determined bacterial repertoire.

### Claim 39

A method of assessing the need of an individual for optimized microbial supplementation or predicting the microbial composition of the gut microbiota of the said individual by determining the secretor/non secretor blood group status of the individual.

### Claim 40 (depends on 39)

The method according to claim 39, wherein the predicted microbial composition is related to at least one of the bacterial group of the list: Bacteroides fragilis group, Clostridium leptum group, and/or Eubacterium rectale-Clostridium coccoides-group.

### Claim 41

A method for determining the balance of gut microbiota of an individual, the method comprising the steps of:
determining secretor/non-secretor genotype of an individual,
determining the composition of gut microbiota of the said individual,
comparing the composition of the gut microbiota of the said individual to the typical composition of gut microbiota according to the secretor/non-secretor genotype.

### Claim 42

A method of estimating a dose of microbial supplementation needed for a desired effect in an individual, or augmenting stabilisation of mucosal microbiota of an individual in disorders related to, or after treatments leading to unbalance of mucosal microbiota by determining the secretor/non secretor blood group status of the individual.
